Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACP 01

Drug Profile

ACP 01

Alternative Names: ACP-01; Angiogenic Cell Precursors - Hemostemix; Endothelial progenitor cells - Hemostemix; VesCell

Latest Information Update: 06 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheraVitae
  • Developer Hemostemix; Mahidol University; TheraVitae
  • Class Anti-ischaemics; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Peripheral arterial disorders; Thromboangiitis obliterans
  • No development reported Angina pectoris; Cardiomyopathies; Heart failure

Most Recent Events

  • 04 Feb 2019 Hemostemix applies for Orphan Drug status in Peripheral arterial disorders (Critical limb ischaemia) in USA
  • 08 Nov 2018 Hemostemix has patents pending for cell therapies in World
  • 08 Nov 2018 Hemostemix has patents protection for cell therapies in World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top